INSTEM Business Summary
Number of employees: 500
Sales per Business
| GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Study Management
43.6
%
| 20 | 44.0 % | 26 | 43.6 % | +26.59% |
Clinical Trial Acceleration
29.6
%
| 13 | 27.6 % | 17 | 29.6 % | +37.06% |
Regulatory Solutions
20.4
%
| 10 | 21.8 % | 12 | 20.4 % | +20.22% |
In Silico Solutions
6.4
%
| 3 | 6.6 % | 4 | 6.4 % | +24.42% |
Sales per region
| GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
United States
59.8
%
| 27 | 58.3 % | 35 | 59.8 % | +31.14% |
Rest of World
19.6
%
| 8 | 17.8 % | 12 | 19.6 % | +41.40% |
Europe
15.0
%
| 7 | 16.2 % | 9 | 15.0 % | +18.34% |
United Kingdom
5.6
%
| 4 | 7.7 % | 3 | 5.6 % | -6.92% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Philip Reason
CEO | Chief Executive Officer | 62 | - |
Nigel Goldsmith
DFI | Director of Finance/CFO | 62 | 11-11-28 |
Vince D’Angelo
CMP | Compliance Officer | - | 87-12-31 |
| Chief Operating Officer | - | 17-01-08 | |
Gordon Baxter
CTO | Chief Tech/Sci/R&D Officer | 63 | 10-12-31 |
Mark Poggi
SAM | Sales & Marketing | - | 22-12-31 |
Eve Leconte
HRO | Human Resources Officer | - | - |
Adrian Gare
PRN | Corporate Officer/Principal | - | 10-03-31 |
John L. Alarcon
PRN | Corporate Officer/Principal | - | 18-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Riaz Bandali
BRD | Director/Board Member | 55 | 21-11-30 |
Mike McGoun
BRD | Director/Board Member | 76 | - |
David Gare
CHM | Chairman | 81 | 68-12-31 |
Nigel Goldsmith
DFI | Director of Finance/CFO | 62 | 11-11-28 |
Philip Reason
CEO | Chief Executive Officer | 62 | - |
John Leveille
BRD | Director/Board Member | - | - |
Mary Dolson
BRD | Director/Board Member | - | 23-01-08 |
Company contact information
Sector
This company's sector is not yet available
